Lunai Bioworks launches Pathfinder Consortium to develop chemical countermeasures in 36 months

Reuters03-19

<a href="https://laohu8.com/S/LNAI">Lunai Bioworks</a> launches <a href="https://laohu8.com/S/PF1.AU">Pathfinder</a> Consortium to develop chemical countermeasures in 36 months

Lunai Bioworks said its BioSymetrics unit formed the Pathfinder Consortium to coordinate academic, military, and biotech efforts on chemical countermeasure discovery and development.
The company described a development model aiming to complete efficacy and safety steps in about 36 months, including a 50-person Phase I safety study.
The program includes screening in yeast and cell-based systems, followed by validation in FDA-recognized zebrafish models.
Lunai said validated countermeasures are typically procured for U.S. government stockpiling programs ranging from USD 400 million to USD 1.2 billion per program.
Named collaborators include Calum MacRae, Vik Bebarta, Randall Peterson, and Vincent Jo Davidson.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603190957PR_NEWS_USPR_____LA14527) on March 19, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620226176?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 21:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620226176","market":"fut","top_or_hot":-1,"title":"Lunai Bioworks launches Pathfinder Consortium to develop chemical countermeasures in 36 months","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LNAI\">Lunai Bioworks</a> launches <a href=\"https://laohu8.com/S/PF1.AU\">Pathfinder</a> Consortium to develop chemical countermeasures in 36 months\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          <a href=\"https://laohu8.com/S/RENB\">Lunai Bioworks</a> said its BioSymetrics unit formed the Pathfinder Consortium to coordinate academic, military, and biotech efforts on chemical countermeasure discovery and development.\n        </li>\n<li>\n          The company described a development model aiming to complete efficacy and safety steps in about 36 months, including a 50-person Phase I safety study.\n        </li>\n<li>\n          The program includes screening in yeast and cell-based systems, followed by validation in FDA-recognized zebrafish models.\n        </li>\n<li>\n          Lunai said validated countermeasures are typically procured for U.S. government stockpiling programs ranging from USD 400 million to USD 1.2 billion per program.\n        </li>\n<li>\n          Named collaborators include Calum MacRae, Vik Bebarta, Randall Peterson, and Vincent Jo Davidson.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603190957PR_NEWS_USPR_____LA14527) on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lunai Bioworks launches Pathfinder Consortium to develop chemical countermeasures in 36 months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLunai Bioworks launches Pathfinder Consortium to develop chemical countermeasures in 36 months\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-19 21:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LNAI\">Lunai Bioworks</a> launches <a href=\"https://laohu8.com/S/PF1.AU\">Pathfinder</a> Consortium to develop chemical countermeasures in 36 months\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          <a href=\"https://laohu8.com/S/RENB\">Lunai Bioworks</a> said its BioSymetrics unit formed the Pathfinder Consortium to coordinate academic, military, and biotech efforts on chemical countermeasure discovery and development.\n        </li>\n<li>\n          The company described a development model aiming to complete efficacy and safety steps in about 36 months, including a 50-person Phase I safety study.\n        </li>\n<li>\n          The program includes screening in yeast and cell-based systems, followed by validation in FDA-recognized zebrafish models.\n        </li>\n<li>\n          Lunai said validated countermeasures are typically procured for U.S. government stockpiling programs ranging from USD 400 million to USD 1.2 billion per program.\n        </li>\n<li>\n          Named collaborators include Calum MacRae, Vik Bebarta, Randall Peterson, and Vincent Jo Davidson.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603190957PR_NEWS_USPR_____LA14527) on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LNAI","symbol_name":"Lunai Bioworks","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL3y24gL:1","article_id":"2620226176","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620226176","pubTimestamp":1773928715,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lunai Bioworks said its BioSymetrics unit formed the Pathfinder Consortium to coordinate academic, military, and biotech efforts on chemical countermeasure discovery and development.The company described a development model aiming to complete efficacy and safety steps in about 36 months, including a 50-person Phase I safety study.The program includes screening in yeast and cell-based systems, followed by validation in FDA-recognized zebrafish models.Lunai said validated countermeasures are typically procured for U.S. government stockpiling programs ranging from USD 400 million to USD 1.2 billion per program.Named collaborators include Calum MacRae, Vik Bebarta, Randall Peterson, and Vincent Jo Davidson.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LNAI":"Lunai Bioworks","BK4139":"生物科技"},"translate_title":"Lunai Bioworks发起探路者联盟36个月研发化学对策","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LNAI":0.9},"content_text":"Lunai Bioworks launches Pathfinder Consortium to develop chemical countermeasures in 36 months\n    \n\n\nLunai Bioworks said its BioSymetrics unit formed the Pathfinder Consortium to coordinate academic, military, and biotech efforts on chemical countermeasure discovery and development.\n        \n\n          The company described a development model aiming to complete efficacy and safety steps in about 36 months, including a 50-person Phase I safety study.\n        \n\n          The program includes screening in yeast and cell-based systems, followed by validation in FDA-recognized zebrafish models.\n        \n\n          Lunai said validated countermeasures are typically procured for U.S. government stockpiling programs ranging from USD 400 million to USD 1.2 billion per program.\n        \n\n          Named collaborators include Calum MacRae, Vik Bebarta, Randall Peterson, and Vincent Jo Davidson.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603190957PR_NEWS_USPR_____LA14527) on March 19, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620226176","isCrawlerRequest":true}